期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

类风湿关节炎分子靶向治疗新药的研究进展 被引量：9

Research progress of drugs targeted therapy for rheumatoid arthritis
原文传递
导出
摘要 类风湿关节炎(RA)是一种自身免疫性疾病,发病率和致残率高。随着对RA发病机制研究的深入,RA分子靶向治疗药物相继出现。本文综述近年来以细胞因子、免疫细胞以及信号转导过程中各种酶为靶点的分子药物研究。 Rheumatoid arthritis（RA） is a common chronic and systematic autoimmune disease with considerable morbidity and mortality.With the research progress on RA pathological mechanism,several drugs targeted on cytokines,immune cells and enzymes in regulate signal transduction process have been developed.This review summarizes the progress of targeted drug therapy for RA.
作者 郑红艳 吴学军 刘全海
机构地区 中国医药工业研究总院上海医药工业研究院
出处 《世界临床药物》 CAS 2013年第5期306-311,共6页 World Clinical Drug
关键词 类风湿关节炎 分子靶点 肿瘤坏死因子α抑制剂 白介素-1拮抗剂 白介素-6拮抗剂 rheumatoid arthritis molecular target tumor necrosis factor a inhibitor interleukin-1 antagonist interleukin-6 antagonist
分类号 R593.22 [医药卫生—内科学] R976 [医药卫生—药品]
  • 相关文献

参考文献38

  • 1St Clair EW, van der Heigde D, SmolenJS, et al. Combination of infliximab and methotrexae therapy for early rheumatoid arthritis: a randomized, controlled trial[J] . Arthritis Rheum, 2004, 50 (11): 3432-3443.
  • 2Breedveld FC,Weisman MH, Kavanaugh AF, et al. Adalimumab plus methotrexate versus methotrexate or adalimumab alone in methotrexatenave patients with early aggressive rheumatoid arthritis:results of the PREMIER study] J]. Arthritis Rheum, 2006, 54 (1): 26-37.
  • 3van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with Rheumatoid arthritis[J]. Arthritis Rheum, 2007, 56 (12): 3928-3939.
  • 4Keystone E, Freundlich B, Schiff M, et a1. Patients with moderate rheumatoid arthritis (RA) achieve better disease aetivity states with etanereept treatment than patients withsevere RA[J].J Rheumatol, 2009, 36 (3): 522-531.
  • 5KekowJ, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial[J] . Ann Rheum Dis, 2010, 69 (1): 222-225.
  • 6Doyle MK, Rahman MU, HanC, et aI. Treatment with infliximab plus methotrexate improvesanemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multiecenter, double-blind, randomized clinical trials[J] . Semin Arthritis Rheum, 2009, 39 (2): 123-131.
  • 7Wakabayashi H, Sudo A, Hasegawa M, et al. Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis[J] . Clin Rheumatol, 2010, 29 (6): 671-675.
  • 8Breedveld FC, Weisman MH, Kavanangh AF, et aI. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment[J] . Arthritis Rheum, 2006,54 (J): 26-37.
  • 9Chen DY, Chou SJ, Hsieh TY, et aI. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwan Residents patients with active rheumatoid arthritis[J].J F ormos Med Assec, 2009, lOS (4) : 310-319.
  • 10Kavanaugh A, Mcinnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis.twenty- four-week efficacy and safety results of a randomized placebo-controlled study[J]. Arthritis Rheum, 2009,60 (4): 976-9S6.

二级参考文献31

  • 1Bugatti S, Codullo V, Caporali R, et al. B cells in rheuma- toid arthritis. Autoimmun Rev, 2007, 7 : 137 - 142.
  • 2Mandik-Nayak L, Ridge N, Fields M, et al. Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol, 2008, 20 : 639 ~ 645.
  • 3Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest, 2005, 115 : 3083 -3092.
  • 4Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T ceil-independent antibodyresponses. J Clin Invest, 2010, 120 : 214 -222.
  • 5Edwards JC, Cambridge G. Sustained improvement in rheu- matoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 2001, 40 : 205- 211.
  • 6Kausar F, Mustafa K, Sweis G, et al. Ocrelizurnab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther, 2009, 9 : 889-895.
  • 7Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizum- ab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase Ⅰ/Ⅱ randomized, blinded, placebo-controlled, dose-ranging stud- y. Arthritis Rheum, 2008, 58 : 2652 -2661.
  • 8Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofa- tumumab produces substantial changes in membrane struc- ture preceding cell lysis. J Immunol, 2008, 181 : 822 - 832.
  • 9Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody for treatment of rheu- matoid arthritis patients with an inadequate response to one or more DMARDs: results of a Double-Blind, Randomized, Placebo-Controlled, Phase I/II Study. Arthritis Rheum, 2010, 62 : 2227-2238.
  • 10McKay J, Chwalinska-Sadowska H, Boling E, et al. Beli- mumab, a fully human monoclonal antibody to B-Lympho-cyte stimulator, combined with standard of care therapy re- duces the signs and symptoms of rheumatoid arthritis in a heterogenous subject population. Arthritis Rheum, 2005, 52 : S710-S711.

共引文献19

同被引文献100

引证文献9

二级引证文献51

世界临床药物
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部